PREMATURE OVARIAN INSSUFICIENCY

Why get tested?

The test allows to identify subjects with ovarian failure and oocyte depletion before the age of physiological menopause. It is recommended in women with primary, secondary amenorrhea or in family members of affected subjects.

What test see?

The test screens for 29 key genes associated with premature ovarian failure (BMP15, FIGLA, NOBOX, NR5A1, STAG3, ERCC6, PGRMC1, DACH2, GDF9, FOXL2, SYCE1, FLJ22792, POU5F1, TGFBR3, INHA, SPIDR, FOXO3, SOHLH1, SOHLH2, NANOS3, HFM1, SYNE1, FANCM, MSH5, FSHR, MCM9, MRPS22, PSMC3IP, NUP107).

How is the test administered on?

The genetic test consists in the execution of a blood sample, in the extraction of the genomic DNA and in the analysis of the entire coding sequence and related exon / intron junctions of the genes BMP15, FIGLA, NOBOX, NR5A1, STAG3, ERCC6, PGRMC1, DACH2, GDF9, FOXL2, SYCE1, FLJ22792, POU5F1, TGFBR3, INHA, SPIDR, FOXO3, SOHLH1, SOHLH2, NANOS3, HFM1, SYNE1, FANCM, MSH5, FSHR, MCM9, MRPS22, NUPMC7IP and NUP107 with NGS technology. The quantification of the number of CGG triplets in the FMR1 gene responsible for Fragile X Syndrome, is performed by PCR assay from genomic DNA.

Turnaround Times

Results in about 12–14 weeks.

Sensitivity and specificity

Analytical sensitivity and specificity > 99% for the sequenced gene panel.

Documents

Forms
Notice

Fill out the form for further information

    * You are a